Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Triple Negative Breast Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Melanoma 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Thyroid Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Recurrence 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1NSCLC 1Gastrointestinal Stromal Tumors 1Gastro-enteropancreatic neuroendocrine tumor 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Cervical Cancer Metastatic 1Carcinoma, Transitional Cell 1BRCA-Mutated Breast Carcinoma 1Advanced Solid Tumor 1

Interventions

Carboplatin 361Pemetrexed 276Cisplatin 230Paclitaxel 213Docetaxel 205Gemcitabine 160Erlotinib Hydrochloride 150Bevacizumab 132pembrolizumab 129Radiotherapy 114Nivolumab 88durvalumab 84Drug Therapy 84osimertinib 82atezolizumab 58Vinorelbine 53Gefitinib 53Radiosurgery 50Cetuximab 39Taxes 37130-nm albumin-bound paclitaxel 36Ipilimumab 34anlotinib 33Surgical Procedures, Operative 33Magnetic Resonance Spectroscopy 33Etoposide 30Albumin-Bound Paclitaxel 29tislelizumab 27icotinib 27aflutinib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Non-Small-Cell Lung × famitinib × Clear all
NCT06336954 2024-03-29

Adibelimab, Famitinib and Chemotherapy for Advanced NSCLC After PD-1 Inhibitor Failure

Second Affiliated Hospital of Xi'an Jiaotong University

Phase 2 Not yet recruiting
40 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02356991 2019-11-04

A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Suspended
137 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡